warfarin

This page shows the latest warfarin news and features for those working in and with pharma, biotech and healthcare.

Ionis reports positive phase 2b results for fesomersen in thrombosis prevention

Current anti-thrombotic treatments include anticoagulants such as warfarin, Factor Xa inhibitors and thrombin inhibitors.

FDA clears first generics of Pfizer/BMS’ anticoagulant Eliquis

Unlike older anticoagulants like warfarin, “direct oral anticoagulants…do not require repeated blood testing,” said Woodcock.
Xarelto no better than aspirin in secondary stroke study

The overall NOAC market is growing strongly in the face of a string of new studies showing the new drugs' benefits over older anticoagulants such as warfarin, but Xarelto has seen
Xarelto beats aspirin for recurrent blood clots

Meanwhile, the overall NOAC market is growing strongly in the face of a string of new studies showing the new drugs' benefits over older anticoagulants such as warfarin.
Bayer defends Xarelto as pivotal trial scrutinised

The trial used a device called INRatio, manufactured by Alere, to determine whether doses of warfarin should be adjusted to keep the drug in the right therapeutic range. ... The implication is that patients on warfarin may have been more prone to bleeds
Daiichi Sankyo licenses clot-busting antibody

Meanwhile, anticoagulants such as warfarin and the newer novel oral anticoagulant (NOAC) class can prevent clots from forming but are unable to dissolve them when already present.

More from news
Approximately 1 fully matching, plus 73 partially matching documents found.

Immuno-oncology is fundamentally changing what value means, but how quickly can the pharma marketing, educational and service model change to reflect that?

Specialist clinics, required to safely manage the potentially tricky long-term use of warfarin, were well-established and represented a significant drain on NHS resources. ... NOACs were far safer for patients and did not have anywhere near the same
Bringing about digital health change

Roche believes it is on to a winner with its CoaguChek system, developed in collaboration with QL, to help warfarin patients self monitor so they don't have to travel to
Pharma–payer partnerships – rhetoric or reality?

The class is likely to replace the current standard of care (warfarin) which has been around for over 50 years. ... Despite being considered a 'dirty' drug warfarin has spawned the development of complex blood monitoring clinics and associated medical
Modern anticoagulants threaten status quo

Warfarin, an oral vitamin K antagonist (VKA) approved in the early 1950s, has ruled the anticoagulant market for nearly six decades. ... Interestingly, a study published in Stroke in March 2012 found that dabigatran etexilate was a cost-effective

More from intelligence
Approximately 0 fully matching, plus 4 partially matching documents found.

Exciting Medical Writer Career Opportunity for Postdoc, Medcomms: Highly competitive salary

Principal Medical Writer/ Scientific Lead, Medcomms, £5K joining...: Highly competitive salary

Market Access Director, six figure base salary and £5K joining b...: Highly competitive salary

Add my company

An Integrated Marketing Communications Agency with a passion for Intelligent Strategy, Compelling Creativity and Professional Delivery....

Virtual Steering Committee & Peer Influence Program: In this customer story, we describe the methodology and results of our client’s ongoing Virtual Steering Committee & Peer Influence program....
Meeting healthcare’s rising challenges: The journey to discover novel therapies through digital innovation and ensure scientific advances achieve their potential...
Report gives insights to address gaps in HCP engagement: How does Pharma-HCP engagement need to evolve in today's digital landscape?...

Email:
Password: